Every 10-Q that Revelation Biosciences, Inc. (REVB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow REVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REVB filings page.
Revelation Biosciences, a clinical-stage biotech developing Gemini-based kidney therapies GEM-AKI and GEM-CKD, reported a Q2 2026 net loss of $3.3 million and a six-month net loss of $6.3 million. Operating expenses increased as GEM-AKI clinical and manufacturing spend, new facility costs, and stock-based compensation rose.
Cash and cash equivalents were $11.5 million and total assets $12.5 million as of June 30, 2026, with stockholders’ equity of $10.1 million and an accumulated deficit of $55.8 million. Since inception, the company has raised $75.9 million, including $6.7 million in January 2026 from a Class I warrant inducement, and had 3.9 million common shares outstanding plus 8.9 million shares underlying warrants.
Management states that existing cash will not sustain operations for 12 months after issuance of these financial statements, creating substantial doubt about continuing as a going concern. After quarter-end, Revelation adopted a stockholder rights plan and described potential Nasdaq delisting risk under a proposed $5 million market-value continued listing rule.
Revelation Biosciences (REVB) reported another loss-making quarter as it advances kidney disease programs GEM‑AKI and GEM‑CKD. For the three months ended March 31, 2026, the company posted a net loss of $3.0 million, wider than $2.1 million a year earlier.
Operating expenses rose to $3.1 million, driven by higher GEM‑AKI development and manufacturing costs, stock-based compensation, and new facility expenses. Cash and cash equivalents increased to $14.1 million, helped by $6.7 million of net proceeds from a Class I warrant inducement, while shares outstanding more than doubled to 3,908,420.
Management states current cash will not sustain operations for 12 months after the financial statements were issued, raising substantial doubt about the company’s ability to continue as a going concern. Revelation expects to seek additional equity or debt financing, and holds significant outstanding warrants that could further affect existing shareholders.
Revelation Biosciences (REVB) reported Q3 2025 results, highlighting higher liquidity alongside a continued net loss and a going concern warning. Cash and cash equivalents were $12.7 million as of September 30, 2025, up from $6.5 million at year-end, supported by financing activity.
For the quarter, the company recorded a net loss of $1.91 million on operating expenses of $1.94 million (R&D $0.92 million; G&A $1.02 million). For the nine months, the net loss was $6.40 million. Stockholders’ equity rose to $11.0 million. The share count increased following two reverse stock splits in 2025 and subsequent warrant-related issuances.
Management disclosed that current cash is not expected to sustain operations within one year after issuance of the financial statements, indicating substantial doubt about continuing as a going concern. Financing events included the May 2025 public offering with net proceeds of $3.4 million and a September 2025 Class H warrant inducement generating net proceeds of $8.7 million. As of November 4, 2025, 5,924,137 shares were outstanding.